Pholcodine

CHEMBL2105224 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
398.5 g/mol
LogP
0.8
Phase
4

Pholcodine is an opioid cough suppressant (antitussive) structurally related to codeine that acts on mu-opioid receptors in the medullary cough center to suppress the cough reflex. It is used for the symptomatic relief of dry, non-productive cough, and unlike codeine, has minimal analgesic activity and lower abuse potential, though it has been associated with sensitization to neuromuscular blocking agents.

分子量

398.5000 g/mol

LogP

0.80

TPSA

54.40 Ų

リピンスキーの五則

適合

作用機序

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN1CC[C@]23c4c5ccc(OCCN6CCOCC6)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5

InChI

InChI=1S/C23H30N2O4/c1-24-7-6-23-16-3-4-18(26)22(23)29-21-19(5-2-15(20(21)23)14-17(16)24)28-13-10-25-8-11-27-12-9-25/h2-5,16-18,22,26H,6-14H2,1H3/t16-,17+,18-,22-,23-/m0/s1

Molecular Formula

C23H30N2O4

HBD / HBA

1 / 6

回転可能結合数

4

重原子数

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Pholcodine is an opioid cough suppressant (antitussive) structurally related to codeine that acts on mu-opioid receptors in the medullary cough center to suppress the cough reflex. It is used for the symptomatic relief of dry, non-productive cough, and unlike codeine, has minimal analgesic activity and lower abuse potential, though it has been associated with sensitization to neuromuscular blocking agents.

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Yes, Pholcodine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105224. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5311356. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.